A combination of doxorubicin and PRIMA-1 had a synergistic effect on p53 accumulation in glioma cells, increasing p53 refolding, inducing p21 and bax, downregulating Bcl-2, and promoting apoptosis [334]. Here, CDKN1A is linked to central nervous system cancer.